NEW YORK, August 28, 2017 /PRNewswire/ --
If you want a Stock Review on EXEL, GERN, INO, or ITCI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,265.64, down 0.09%; the Dow Jones Industrial Average edged 0.14% higher, to finish at 21,813.67; and the S&P 500 closed at 2,443.05, marginally gaining 0.17%. Further, seven out of nine sectors finished the trading session in green. DailyStockTracker.com has initiated research reports on the following Biotechnology stocks: Exelixis Inc. (NASDAQ: EXEL), Geron Corp. (NASDAQ: GERN), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Daily Stock Tracker published comprehensive and free research reports on these stocks today at: http://dailystocktracker.com/register/
South San Francisco, California headquartered Exelixis Inc.'s stock finished Friday's session 0.59% lower at $27.16 with a total trading volume of 2.12 million shares. The stock has gained 40.36% over the past three months, 148.95% in the previous twelve months, and 82.16% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 5.62% and 29.11%, respectively. Moreover, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have a Relative Strength Index (RSI) of 56.91. EXEL complete research report is just a click away and free at: http://dailystocktracker.com/registration/?symbol=EXEL
Shares in Menlo Park, California-based Geron Corp. declined 2.91%, ending last Friday's session at $2.00 with a total trading volume of 664,348 shares. The Company's shares are trading below their 50-day moving average by 22.20%. Moreover, shares of Geron, which operates as a biopharmaceutical company, have an RSI of 28.32. The complimentary report on GERN can be downloaded at: http://dailystocktracker.com/registration/?symbol=GERN
On Friday, Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock saw a decline of 3.11%, to close the day at $5.61 with a total trading volume of 891,722 shares. The Company's shares have advanced 1.81% in the last one month. The stock is trading below its 50-day moving average by 16.54%. Additionally, shares of Inovio Pharmaceuticals, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have an RSI of 40.26. Sign up for your complimentary research report on INO at: http://dailystocktracker.com/registration/?symbol=INO
Intra Cellular Therapies
Shares in New York headquartered Intra-Cellular Therapies Inc. ended the day 3.96% lower at $15.27. A total volume of 1.13 million shares was traded, which was above their three months average volume of 496.61 thousand shares. The stock has gained 30.96% in the last one month and 50.30% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 28.27% and 16.34%, respectively. Furthermore, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 70.75.
On August 24th, 2017, research firm JMP Securities upgraded the Company's stock rating from 'Market Perform' to 'Market Outperform'. Get free access to your research report on ITCI at: http://dailystocktracker.com/registration/?symbol=ITCI
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.